GlaxoSmithKline's Blood Cancer Drug Dreamm-1 Study Results Positive
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday it received "further positive" data from its Dreamm-1 study of patients with relapsed multiple myeloma.Multiple myeloma Read More